Daily Sepsis Research Analysis
Analyzed 37 papers and selected 3 impactful papers.
Summary
Three papers advance sepsis science across translational spectra: a meta-analysis links complement signatures (lower C3/C4, higher C4a) with mortality; a Nature Communications preclinical study demonstrates neutrophil-hitchhiking hybrid nanovesicles delivering polymyxin B that improve survival in murine sepsis models; and a proteomic study shows bacterial sepsis shares CNS biomarkers with Alzheimer’s disease, implying overlapping neurodegenerative mechanisms.
Research Themes
- Complement signatures as mortality biomarkers and targets in sepsis
- Neutrophil-hitchhiking hybrid nanovesicles for targeted antibiotic delivery
- Convergence of neurodegeneration biomarkers between bacterial sepsis and Alzheimer's disease
Selected Articles
1. Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.
A hybrid cross-species nanovesicle platform that co-opts neutrophils to carry polymyxin B to infection foci reduced bacterial burden, dampened cytokines, and improved survival in murine models of carbapenem-resistant Gram-negative infections and sepsis. The vesicles exploit bacterial PAMPs for neutrophil uptake and release cargo upon inflammatory cues.
Impact: Introduces a mechanistically novel, neutrophil-hitchhiking antibiotic delivery system that improves sepsis survival in resistant pathogens, addressing a critical gap in AMR-era sepsis therapeutics.
Clinical Implications: If safety and immunogenicity translate to humans, neutrophil-guided vesicle delivery could enable targeted dosing of toxic antibiotics like polymyxin B, potentially enhancing efficacy against deep-seated infections while limiting systemic toxicity.
Key Findings
- PMB@LNV-SyBV integrates lemon exosomes and bacterial vesicles, with cholesterol improving drug loading.
- Neutrophils efficiently internalize PMB@LNV-SyBV via inherited PAMPs, enabling trafficking to infection sites and stimulus-responsive release.
- In K. pneumoniae pneumonia and K. pneumoniae/E. coli bloodstream infection models, the platform reduced bacterial load, modulated pro-inflammatory cytokines, and increased sepsis survival.
Methodological Strengths
- Efficacy demonstrated in two distinct in vivo infection models (pneumonia and bloodstream infection).
- Mechanistic validation of neutrophil-mediated uptake and inflammatory stimulus-triggered release.
Limitations
- Preclinical animal study; human safety, immunogenicity, and pharmacokinetics remain unknown.
- Manufacturing scalability, batch consistency, and regulatory pathways for hybrid vesicles are untested.
Future Directions: Advance to GLP toxicology, dose-ranging, and biodistribution studies; evaluate efficacy versus standard-of-care in large-animal sepsis models; explore broader antibiotic payloads and combination strategies.
Hybrid vesicles are increasingly employed as nanocarrier systems for drug delivery owing to their versatile functionalities. This study presents a multifunctional vesicle delivery platform, designated PMB@LNV-SyBV, which integrates anti-inflammatory lemon-derived exosomes and attenuated bacterial vesicles to deliver polymyxin B (PMB). The incorporation of exogenous cholesterol enhances the drug-loading capacity of these vesicles. Antimicrobial assays confirm that PMB@LNV-SyBV effectively targets carbapenem-resistant Gram-negative bacteria. By inheriting pathogen-associated molecular patterns from native bacteria, PMB@LNV-SyBV is efficiently recognized and internalized by neutrophils, enabling it to reach infection sites alongside neutrophil recruitment. Subsequently, the vesicles are released from neutrophils in response to inflammatory stimuli. In infection models involving Klebsiella pneumoniae-induced mouse pneumonia and K. pneumoniae/Escherichia coli-induced mouse bloodstream infections, PMB@LNV-SyBV significantly reduces bacterial load, modulates pro-inflammatory cytokine release, and increases sepsis survival rates. With its high yield and favorable biocompatibility, the multifunctional PMB@LNV-SyBV represents a promising therapeutic platform for the clinical management of carbapenem-resistant bacterial infections.
2. Systematic review and meta-analysis of humoral immunity proteins and mortality in sepsis.
Across 36 studies (6,330 patients), survivors had higher C3 and C4, while C4a and IgA were lower, with no differences in IgG, IgM, C5, C5a, or HBP. Sensitivity analyses using MIMIC-IV and proteomics corroborated early complement depletion in non-survivors, positioning complement as a prognostic biomarker and potential therapeutic target.
Impact: Provides quantitative, multi-cohort evidence linking complement profiles to mortality, informing risk stratification and guiding complement-targeted therapeutic development.
Clinical Implications: Measurement of complement components (C3, C4, C4a) could augment prognostication and potentially select patients for trials of complement-modulating therapies in sepsis.
Key Findings
- Survivors had higher C3 (SMD 0.53) and C4 (SMD 0.51) compared with non-survivors.
- Survivors had lower C4a (SMD -1.17) and IgA (SMD -0.21); no differences for IgG, IgM, C5, C5a, or heparin-binding protein.
- Sensitivity analyses using MIMIC-IV (n=2,452) and proteomic datasets corroborated early depletion of classical complement components in non-survivors.
Methodological Strengths
- Comprehensive dual-database search with random-effects meta-analysis.
- Robust sensitivity analyses incorporating ICU EHR (MIMIC-IV) and proteomic datasets.
Limitations
- Heterogeneity in timing of sampling, assays, and patient populations across studies.
- Observational data preclude causal inference; residual confounding likely.
Future Directions: Prospective validation of complement-based prognostic panels and interventional trials testing complement modulation (e.g., C3/C4 pathway inhibitors) in biomarker-enriched sepsis cohorts.
PURPOSE: Humoral immunity proteins-immunoglobulins, complement proteins, and antimicrobial peptides-have key antimicrobial and immunomodulatory functions in sepsis. We hypothesised that their circulating levels are lower in non-survivors, potentially resulting in impaired bacterial clearance and persistent or recurrent infections. METHODS: We performed a systematic review and meta-analysis evaluating differences in humoral immunity proteins between survivors and non-survivors in adult patients with sepsis. PubMed and Embase were searched without date restrictions. Random-effects meta-analyses were used to estimate pooled standardised mean differences (SMD) with 95% confidence intervals (CI). Sensitivity analyses included data from the MIMIC-IV ICU database, and further supplemented by three proteomic studies. RESULTS: Thirty-six studies including 6,330 patients were analysed. Thirteen reported on immunoglobulins, 17 on complement proteins, and 7 on the antimicrobial peptide heparin-binding protein (HBP). Survivors had significantly higher levels of complement proteins C3 (SMD 0.53 [0.07-0.99]) and C4 (SMD 0.51 [0.09-0.94]) compared to non-survivors. Conversely, C4a (SMD - 1.17 [-1.77 to - 0.56]) and IgA (SMD - 0.21 [-0.39 to - 0.03]) were significantly lower in survivors. No differences were found for IgG (SMD 0.00 [-0.18 to 0.18]), IgM (SMD - 0.02 [-0.13 to 0.08]), C5, C5a, or HBP. Sensitivity analyses using MIMIC-IV (n = 2,452) and proteomic datasets supported these findings. Proteomic data revealed early depletion of classical complement components (C3, C4B) and regulatory proteins in non-survivors. CONCLUSION: Sepsis non-survivors exhibit lower C3 and C4 levels and higher C4a, consistent with complement activation and/or depletion. Complement proteins may serve as potential biomarkers and therapeutic targets in sepsis.
3. Developing Topics.
Using an attomolar-sensitivity multiplex proteomic platform, bacterial sepsis showed partial overlap with Alzheimer’s disease in plasma CNS biomarker patterns, including synaptic (NRGN, SNAP25), neuropeptide (NPY), tau (MAPT), alpha-synuclein (SNCA), and amyloid-beta isoforms. Viral sepsis formed a distinct cluster, suggesting pathogen-specific neurobiological signatures.
Impact: Bridges sepsis and neurodegeneration by identifying shared CNS plasma biomarker patterns, informing mechanisms of post-sepsis cognitive decline and potential therapeutic targets.
Clinical Implications: Supports monitoring and potential risk stratification for cognitive decline after bacterial sepsis using CNS biomarker panels; highlights distinct trajectories for bacterial versus viral sepsis.
Key Findings
- Principal component analysis showed partial clustering overlap between bacterial sepsis and AD, while viral sepsis clustered separately.
- Shared biomarkers between bacterial sepsis and AD included NRGN, NPY, SNAP25, MAPT, SNCA, and amyloid-beta isoforms.
- AD group was older and had higher APOE carrier frequency; bacterial sepsis had higher severity (SOFA, SAPS3) than viral sepsis.
Methodological Strengths
- High-sensitivity, high-multiplex plasma proteomics (NULISA) spanning 120 CNS biomarkers.
- Comparative multi-cohort design including bacterial sepsis, viral sepsis (COVID-19), AD, and healthy controls with PCA-based pattern analysis.
Limitations
- Cross-sectional design limits causal inference about sepsis-driven neurodegeneration.
- Group differences (age, APOE frequency) and small AD sample may confound biomarker overlap.
Future Directions: Longitudinal studies tracking CNS biomarkers and cognition post-sepsis, pathogen-specific analyses, and interventional trials targeting neuroinflammation/degeneration pathways.
BACKGROUND: Clinical studies indicate an association between hospital-diagnosed infections and the development and progression of AD and other types of dementia. However, the mechanisms by which infection contributes to the decline in cognitive function and the worsening of AD are unknown. This study investigated plasma proteomic biomarkers in patients with sepsis-a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection-admitted to intensive care units (ICUs). We evaluated their overlap with biomarkers associated with AD pathology. METHODS: The study included 263 participants: 122 with bacterial sepsis, 101 with viral sepsis (COVID-19), 20 with AD, and 20 healthy controls (HCs). AD patients were significantly older (median age 77.0 years, IQR: 73.5-79.0) compared to the sepsis cohorts (bacterial: 68.0 [53.0-79.8], viral: 67.0 [57.0-73.0], p < 0.001). The proportion of APOE carriers was highest in the AD group (80%), compared to bacterial (19.7%) and viral sepsis (23.8%) patients (p < 0.001). Illness severity scores (SOFA and SAPS3) were significantly higher in bacterial sepsis patients compared to those with viral sepsis (p < 0.01). 120 CNS proteomic plasma biomarkers of glial cells, neuroinflammation, neurodegeneration, and blood-brain barrier integrity were measured by a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing NULISA™. RESULTS: Principal component analysis (PCA) revealed that bacterial sepsis patients exhibited partial overlap with the AD-positive group, suggesting shared biomarker patterns. In contrast, the viral sepsis group formed a distinct cluster with minimal overlap, and AD-negative controls remained well separated from all other groups. Furthermore, bacterial sepsis showed several biomarkers shared by patients with AD. This includes neurodegenerative and neurological proteins such as neurogranin (NRGN), neuropeptide Y (NPY), synaptosomal-associated protein 25 (SNAP25), microtubule-associated protein tau (MAPT), alpha-synuclein (SNCA), amyloid-beta isoforms (Aβ CONCLUSION: Our results indicate that sepsis and AD share common biomarkers, suggesting that sepsis may exacerbate AD progression and that both conditions may have overlapping pathophysiological mechanisms. Understanding these similarities could be crucial for developing novel therapies targeting neuroinflammation, neurodegeneration, and PICs.